Eagle Pharmaceuticals Inc. (EGRX): Douglas Braunstein of Hudson Executive Capital Appointed Chairman

Page 2 of 7 – SEC Filing
CUSIP No.  269796108
SCHEDULE 13D
Page 2 of 6 Pages
1
 NAMES OF REPORTING PERSON          
    Hudson Executive Capital LP
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)  ☐
 (b)  ☐
3 SEC USE ONLY
4
SOURCE OF FUNDS
             AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)
       ☐
6
CITIZENSHIP OR PLACE OF ORGANIZATION
           Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER
          0
8
SHARED VOTING POWER
          950,600
9
SOLE DISPOSITIVE POWER
          0
10
SHARED DISPOSITIVE POWER
   950,600
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       950,600
12
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES
      ☐
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES
       6.1%(1)
14
TYPE OF REPORTING PERSON
    PN, IA
_______________________________
(1) Calculated based on 15,636,387 shares of common stock, par value $0.001 per share, of Eagle Pharmaceuticals, Inc., outstanding as of May 3, 2016, as reported in Eagle Pharmaceuticals, Inc.’s quarterly report on Form 10-Q for the quarter ended March 31, 2016.

Follow Eagle Pharmaceuticals Inc. (NASDAQ:EGRX)